Pharma's Market

SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

MORE HEADLINES

» Markets | Economy | Companies

- Dems Snare 60 Votes to Move Ahead on Health Care

PHARMA'S MARKET VIDEO

» More

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

Cholesterol Drug Battle: Merck vs. Abbott Labs

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Barbara Ryan, pharma analyst at Deutsche Bank Securities, shares her reaction.

Cholesterol Drug Battle 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Novo Nordisk CEO on Diabetes Epidemic

13 Nov 2009

Diabetes is a global epidemic that presents an estimated $25 billion drug and device market and some predict that number could double over the next several years. Lars Sorensen, CEO of Novo Nordisk, the world's largest diabetes care company, talks to CNBC's Mike Huckman.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Biopharma's Bustin' Out All Over

Published: Monday, 2 Nov 2009 | 12:32 PM ET

Text Size

By: Mike Huckman
CNBC Correspondent

Over the past few days there's been a remarkable confluence of newsflow, most of it positive, out of biopharma.

First the bad news.

New York Attorney General Andrew Cuomo is leading a multi-state lawsuit against biotech giant Amgen [AMGN Loading... () ] over alleged kickbacks. The company says the case is without merit. Then, just a few hours later, on Halloween Eve, the results of the so-called TREAT trial came out. There were nearly twice as many strokes among diabetic, pre-dialysis kidney disease patients who got AMGN's anemia drug Aranesp. Most analysts say the results, while obviously not good, may have already been baked into the stock price. It's also worth noting that Amgen paid for this study. So, it'll be interesting to see how far it might go to help dispel perceptions that drug companies buy only favorable research and try to sweep everything else under the rug. In the press release, Amgen's head of R & D even acknowledges "the risk...will exceed the benefit...."

And now the good stuff.

Where do I start? Dendreon [DNDN Loading... () ] files a little bit earlier than expected for FDA approval of its prostate cancer treatment Provenge. Human Genome Sciences [HGSI Loading... () ] says the second of two late-stage studies on the Lupus drug it shares with GlaxoSmithKline [GSK Loading... () ] met its main goal. Vertex Pharmaceuticals [VRTX Loading... () ] says a mid-stage study shows a twice-a-day version of its experimental hepatitis C drug works as well as the further along three-time-a-day version. It's partners with Johnson & Johnson [JNJ Loading... () ] on that one. Vertex and HGSI both hit new intra-day highs. And finally, Amylin Pharmaceuticals [AMLN Loading... () ] hit a trifecta over the weekend. The FDA okayed use of the diabetes drug Byetta as a stand-alone treatment. The agency did put a new warning on the Byetta label for pancreatitis, but it isn't the more severe "boxed" warning. And the company did a potential $1-billion-plus partnership deal on its developmental obesity drugs. Amylin and Lilly [LLY Loading... () ] are partners on the twice-a-day injectable Byetta. And the pair, along with Alkermes [ALKS Loading... () ], are waiting for the FDA okay of a once-a-week version of the drug.

Today, I interviewed the CEOs of AMLN, HGSI and VRTX. If you missed them, you can check them out here on this blog page as they appear and get posted. Sure, things get hectic when there's so much to keep track of, but it's days like this when I'm glad to be on this beat.

Questions? Comments? and follow me on Twitter at mhuckman